Update of EULAR recommendations for the treatment of systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 76, Issue 8, 2017, Pages 1327-1339

  Kowal Bielecka, Otylia ^a   Fransen, Jaap ^b   Avouac, Jerome ^c   Becker, Mike ^d,e   Kulak, Agnieszka ^a   Allanore, Yannick ^c   Distler, Oliver ^e   Clements, Philip ^f   Cutolo, Maurizio ^g   Czirjak, Laszlo ^h   Damjanov, Nemanja ⁱ   Del Galdo, Francesco ^j   Denton, Christopher P ^k   Distler, Jörg H W ^l   Foeldvari, Ivan ^m   Figelstone, Kim ⁿ   Frerix, Marc ^o   Furst, Daniel E ^f   Guiducci, Serena ^p   Hunzelmann, Nicolas ^q   Khanna, Dinesh ^r   Matucci Cerinic, Marco ^p   Herrick, Ariane L ^s,t   Van Den Hoogen, Frank ^b   Van Laar, Jacob M ^u   Riemekasten, Gabriela ^v   Silver, Richard ^w   Smith, Vanessa ^x   Sulli, Alberto ^g   Tarner, Ingo ^o   Tyndall, Alan ^y   Welling, Joep ^z   Wigley, Frederic ^aa   Valentini, Gabriele ^ab   Walker, Ulrich A ^y   Zulian, Francesco ^ac   Müller Ladner, Ulf ^o   Daikeler, Thomas ^ad   Lanciano, Elisabetta ^ae   Becvár, Radim ^af   Tomcik, Michal ^af   Gińdzieńska Sieskiewicz, Ewa ^a   Cuomo, Giovanna ^ag   Iudici, Michele ^ag   Rednic, Simona ^ah   Vlachoyiannopoulos, Panayiotis G ^ai   Caporali, Roberto ^aj   Carreira, Patricia E ^ak   Novak, Srdan ^al   Minier, Tünde ^am   Kucharz, Eugene J ^an   Gabrielli, Armando ^ao   Moroncini, Gianluca ^ao   Airo', Paolo ^ap   Hesselstrand, Roger ^aq   Martinovic, Duska ^ar   Radic, Mislav ^ar   Marasovic Krstulovic, Daniela ^ar   Braun Moscovici, Yolanda ^as   Balbir Gurman, Alexandra ^as   Lo Monaco, Andrea ^at   Caramaschi, Paola ^au   Morovic Vergles, Jadranka ^av   Henes, Jörg ^aw   Ortiz Santamaria, Vera ^ax   Heitmann, Stefan ^ay   Krasowska, Dorota ^az   Seidel, Matthias F ^ba   Hasler, Paul ^bb   Pereira Da Silva, José A ^bc   Salvador, Maria J ^bc   Stamenkovic, Bojana ^bd   Stankovic, Aleksandra ^bd   Tikly, Mohammed ^be   Ananieva, Lidia P ^bf   Beretta, Lorenzo ^bg   Szucs, Gabriella ^bh   Szamosi, Szilvia ^bh   de la Puente Bujidos, Carlos ^bi   Midtvedt, Øyvind ^bj   Hoffmann Vold, Anna Maria ^bj   Launay, David ^bk   Hachulla, Eric ^bl   Riccieri, Valeria ^bm   Ionescu, Ruxandra ^bn   Opris, Daniela ^bn   Mihai, Carina ^bn   Herrgott, Ilka ^bo   Beyer, Christian ^bp   Ingegnoli, Francesca ^bq   von Mühlen, Carlos Alberto ^br   Alegre Sancho, Juan José ^bs   Beltrán Catalán, Emma ^bs   Aringer, Martin ^bt   Fantana, Julia ^bt   Leuchten, Nicolai ^bt   Tausche, Anne Kathrin ^bt   De Langhe, Ellen ^bu   Vanthuyne, Marie ^bv   Anic, Branimir ^bw   Barešic, Marko ^bw   Mayer, Miroslav ^bw   Üprus, Maria ^bx   Otsa, Kati ^bx   Yavuz, Sule ^by   Granel, Brigitte ^bz   Azevedo, Valderilio F ^ca   Muller, Carolina ^ca   Jimenez, Sergio A ^cb   Popa, Serghei ^cc   Agachi, Svetlana ^cc   Zenone, Thierry ^cd   Stebbings, Simon ^ce   Dockerty, Joanne ^ce   Vacca, Alessandra ^cf   Schollum, Joanna ^cg   Veale, Douglas J ^ch   Toloza, Sergio ^ci   Xu, Dong ^cj   Olas, Jacek ^ck   Rosato, Edoardo ^bm   Foti, Rosario ^cl   Adler, Sabine ^cm   Dan, Diana ^cm   Wiesik Szewczyk, Ewa ^cn   Olesińska, Marzena ^cn   Kayser, Cristiane ^co   Fathi, Nihal ^cp   de la Peña Lefebvre, Paloma García ^cq   Imbert, Bernard ^cr   more..

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c université Paris Cité   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF PÉCS   (Hungary)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^m Hamburg Center for Pediatric Rheumatology   (Germany)

ⁿ Scleroderma Association   (United Kingdom)

^o JUSTUS LIEBIG UNIVERSITY   (Germany)

^p UNIVERSITY OF FLORENCE   (Italy)

^q UNIVERSITY OF COLOGNE   (Germany)

^r UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

^t MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^u UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^v UNIVERSITY OF LÜBECK   (Germany)

^w MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^x GHENT UNIVERSITY   (Belgium)

^y UNIVERSITY OF BASEL   (Switzerland)

^z FESCA Patient Research Partner   (Netherlands)

^aa JOHNS HOPKINS UNIVERSITY   (United States)

^ab SECOND UNIVERSITY OF NAPLES   (Italy)

^ac UNIVERSITY OF PADOVA   (Italy)

^ad UNIVERSITY HOSPITAL BASEL   (Switzerland)

^ae UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^af CHARLES UNIVERSITY   (Czech Republic)

^ag FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^ah IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ai UNIVERSITY OF ATHENS   (Greece)

^aj FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ak HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^al KBC RIJEKA   (Croatia)

^am UNIVERSITY OF PÉCS   (Hungary)

^an MEDICAL UNIVERSITY OF SILESIA   (Poland)

^ao UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^ap SPEDALI CIVILI   (Italy)

^aq LUND UNIVERSITY HOSPITAL   (Sweden)

^ar UNIVERSITY HOSPITAL SPLIT   (Croatia)

^as B Shine Department of Rheumatology   (Israel)

^at UNIVERSITY OF FERRARA   (Italy)

^au UNIVERSITY HOSPITAL OF VERONA   (Italy)

^av UNIVERSITY OF ZAGREB   (Croatia)

^aw UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^ax Rheumatology Granollers General Hospital   (Spain)

^ay MARIENHOSPITAL STUTTGART   (Germany)

^az MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^ba Medizinische Klinik III   (Germany)

^bb CANTONAL HOSPITAL AARAU   (Switzerland)

^bc CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^bd UNIVERSITY OF NI   (Serbia)

^be UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^bf V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^bg FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^bh UNIVERSITY OF DEBRECEN   (Hungary)

^bi HOSPITAL RAMÓN Y CAJAL   (Spain)

^bj OSLO UNIVERSITY HOSPITAL   (Norway)

^bk UNIV LILLE   (France)

^bl LILLE UNIVERSITY HOSPITAL   (France)

^bm SAPIENZA UNIVERSITY OF ROME   (Italy)

^bn CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^bo UNIVERSITY OF MÜNSTER   (Germany)

^bp UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^bq UNIVERSITY OF MILAN   (Italy)

^br Rheuma Clinic   (Brazil)

^bs HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^bt UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^bu UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^bv CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^bw KBC Zagreb   (Croatia)

^bx East Tallin Central Hospital   (Estonia)

^by MARMARA UNIVERSITY   (Turkey)

^bz HÔPITAL NORD   (France)

^ca FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^cb THOMAS JEFFERSON UNIVERSITY   (United States)

^cc STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^cd Department of Medicine   (France)

^ce UNIVERSITY OF OTAGO   (New Zealand)

^cf UNIVERSITY OF CAGLIARI   (Italy)

^cg UNIVERSITY OF WAIKATO   (New Zealand)

^ch ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^ci Hospital San Juan Batista   (Argentina)

^cj PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^ck Szpital Specjalistyczny Im J Dietla   (Poland)

^cl UNIVERSITY OF CATANIA   (Italy)

^cm UNIVERSITY OF BERN   (Switzerland)

^cn NATIONAL INSTITUTE OF GERIATRICS   (Poland)

^co FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^cp Sohag University   (Egypt)

^cq Hospital Universitario Madrid Norte Sanchinarro   (Spain)

^cr GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Cyclophosphamide; Methotrexate; Systemic Sclerosis; Treatment

Indexed keywords

AMBRISENTAN; BOSENTAN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOXETINE; GLUCOCORTICOID; ILOPROST; MACITENTAN; METHOTREXATE; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROKINETIC AGENT; PROSTACYCLIN; PROTON PUMP INHIBITOR; RIOCIGUAT; SILDENAFIL; TADALAFIL; TREPROSTINIL; ENDOTHELIN RECEPTOR ANTAGONIST; PROSTACYCLIN DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL RESEARCH; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FINGER ULCER; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LUNG DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; SKIN DISEASE; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC SCLEROSIS; COMPLICATION; CONSENSUS DEVELOPMENT; DELPHI STUDY; EUROPE; FINGER; GASTROINTESTINAL DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPERTENSION, PULMONARY; KIDNEY DISEASES; LUNG DISEASES; PRACTICE GUIDELINE; RAYNAUD DISEASE; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; ULCER;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DELPHI TECHNIQUE; ENDOTHELIN RECEPTOR ANTAGONISTS; EUROPE; FINGERS; FLUOXETINE; GASTROINTESTINAL DISEASES; GLUCOCORTICOIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; KIDNEY DISEASES; LUNG DISEASES; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS I; PYRAZOLES; PYRIMIDINES; RAYNAUD DISEASE; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; SEROTONIN UPTAKE INHIBITORS; ULCER;

EID: 84995487524     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209909     Document Type: Article

References (102)

1. Nihtyanova SI, Ong VH, Denton CP. Current management strategies for systemic sclerosis. Clin Exp Rheumatol 2014;32(Suppl 81):156-64.
2. Kowal-Bielecka O, Landewé R, Avouac J, et al., EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
3. Walker KM, Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38:1326-8.
4. Dougados M, Betteridge N, Burmester GR, et al., EULAR. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
5. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
6. Avouac J, Kowal-Bielecka O, Landewe R, et al. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009;68:629-34.
7. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
8. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
9. Ettinger WH, Wise RA, Schaffhauser D, et al. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984;77:451-6.
10. Kahan A, Weber S, Amor B, et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). Eur Heart J 1983;4(Suppl C):123-9.
11. Kahan A, Foult JM, Weber S, et al. Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon. Eur Heart J 1985;6:702-5.
12. Kahan A, Amor B, Menkès CJ, et al. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Angiology 1987;38:333-7.
13. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989;298:561-4.
14. Rodeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983;308:880-3.
15. Meyrick Thomas RH, Rademaker M, Grimes SM, et al. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 1987;117:237-41.
16. Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013;72:1696-9.
17. Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.
18. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
19. Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36:2264-8.
20. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010;49:2420-8.
21. Agarwal V, Ghosh P, Sharma A, et al. Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study (abstract). Arthritis Rheum 2010;62(Suppl 10):S872.
22. Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 2012;172:1182-4.
23. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; (2):Cd000953.
24. McHugh NJ, Csuka M, Watson H, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-7.
25. Yardumian DA, Isenberg DA, Rustin M, et al. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-6.
26. Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403-6.
27. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
28. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
29. Belch JJ, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
30. Lau CS, Belch JJ, Madhok R, et al. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 1993;11:35-40.
31. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-7.
32. Black CM, Halkier-Sørensen L, Belch JJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952-60.
33. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999;26:2173-8.
34. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8.
35. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001;40:1038-43.
36. The electronic Medicines Compendium (eMC). https://www.medicines.org.uk/emc/ medicine/25737 (accessed Jul 2016).
37. Seibold JR, Wigley F, Schiopu E, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebocontrolled, multicenter study [abstract]. Arthritis Rheum 2011;63(10 Suppl):S968.
38. Tingey T, Shu J, Smuczek J, et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2013;65:1460-71.
39. Hachulla E, Hatron PY, Carpentier P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 2016;75:1009-15.
40. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
41. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
42. Khanna D, Denton CP, Merkel PA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 2016;315:1975-88.
43. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18.
44. Ghofrani HA, Distler O, Gerhardt F, et al. Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011;154(Suppl 1):S20-33.
45. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014;146:449-75.
46. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
47. Patel T, McKeage K. Macitentan: first global approval. Drugs 2014;74:127-33.
48. Conole D, Scott LJ. Riociguat: first global approval. Drugs 2013;73:1967-75.
49. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119.
50. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
51. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
52. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
53. Food and Drug Administration Drug approval package: flolan (epoprostenol sodium) injection. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 020444s016lbl.pdf (accessed Jul 2016).
54. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
55. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
56. Johnson SR, Feldman BM, Pope JE, et al. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 2009;36:323-9.
57. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005;4:723-30.
58. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
59. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
60. Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009;136:1333-40.
61. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
62. Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011;63:2797-808.
63. Lynch JP III, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155:395-420.
64. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
65. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-8.
66. Lopez-Ovejero JA, Saal SD, D'Angelo WA, et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979;300:1417-19.
67. Helfrich DJ, Banner B, Steen VD, et al. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32:1128-34.
68. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
69. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
70. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008;67:110-16.
71. Guillevin L, Bérezné A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 2012;51:460-7.
72. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100:485-94.
73. Hudson M, Baron M, Tatibouet S, et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014;43:666-72.
74. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-19.
75. DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
76. Montanelli G, Beretta L, Santaniello A, et al. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013;31(Suppl 76):135-9.
77. Hesselstrand R, Scheja A, Wuttge DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012;41:39-43.
78. Iudici M, Fasano S, Iacono D, et al. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol 2014;33:153-64.
79. Pakozdi A, Wilson H, Black CM, et al. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis Clin Exp Rheumatol 2009;27(Suppl 54):5-8.
80. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
81. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;(2):Cd003245.
82. Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013;(5):Cd002095.
83. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009;122:896-903.
84. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink Drugs 2012;72:437-45.
85. Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36:405-13.
86. Horowitz M, Maddern GJ, Maddox A, et al. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987;93:311-15.
87. Wehrmann T, Caspary WF. [Effect of cisapride on esophageal motility in healthy probands and patients with progressive systemic scleroderma]. Klin Wochenschr 1990;68:602-7.
88. Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharmacol 1991;31:683-7.
89. Limburg AJ, Smit AJ, Kleibeuker JH. Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease. Digestion 1991;49:156-60.
90. Wang SJ, La JL, Chen DY, et al. Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 2002;21:43-5.
91. Quigley EM. Cisapride: what can we learn from the rise and fall of a prokinetic J Dig Dis 2011;12:147-56.
92. Fiorucci S, Distrutti E, Gerli R, et al. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol 1994;89:550-5.
93. Verne GN, Eaker EY, Hardy E, et al. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995;40:1892-901.
94. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461-7.
95. Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 2007;13:119-23.
96. Hasler WL. Pharmacotherapy for intestinal motor and sensory disorders. Gastroenterol Clin North Am 2003;32:707-32.
97. Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am 2015;44:97-111.
98. Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008;103:1257-62.
99. Marie I, Ducrotté P, Denis P, et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford) 2009;48:1314-19.
100. Grace E, Shaw C, Whelan K, et al. Review article: small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013;38:674-88.
101. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630-40.
102. Clements PJ, Tashkin D, Roth M, et al. The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheumatol 2015;67(Suppl 10). http://acrabstracts.org/abstract/the-scleroderma-lung-study-ii-sls-ii-shows-thatboth-oral-cyclophosphamide-cyc-and-mycophenolate-mofitil-mmf-are-efficaciousin-treating-progressive-interstitial-lung-disease-ild-in-patients-w/ (accessed 2 Dec 2015).